Summit Technologies' first-quarter results boosted by US sales
This article was originally published in Clinica
Summit Technologies' first-quarter sales have increased 94% compared with the previous year, mainly due to higher US sales of the company's excimer laser system. In March, the Massachusetts-based manufacturer of ophthalmic lasers received US FDA approval for its laser system for phototherapeutic keratectomy (PTK) to treat certain corneal pathologies (see Clinica No 646, p 20).
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.